Drug Trial Radar · NCT00350415
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Apr 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
772
Actual
Start
Jun 2006
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Warner ChilcottIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
Conditions
- Ulcerative Colitis
Interventions
MesalamineDrug
Asacol 400g/day (400 mg tablet), oral, for 6 weeks OR Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients (ITT) in each treatment group who achieve treatment success, defined as symptomatic and endoscopic improvement from baseline at Week 6.Time frame: Week 6
Locations
135 sites in 15 countries. Site status is shown where the registry gives one.
Research Facility
Alabaster, Alabama
Research Facility
Birmingham, Alabama
Research Facility
Tucson, Arizona
Research Facility
Fayetteville, Arkansas
Research Facility
Little Rock, Arkansas
Research Facility
Anaheim, California
Research Facility
Burbank, California
Research Facility
Encinitas, California
Research Facility
Los Angeles, California
Research Facility
Los Angeles, California
Research Facility
Mission Hills, California
Research Facility
Orange, California
Research Facility
Pasadena, California
Research Facility
Roseville, California
Research Facility
Sacramento, California
Research Facility
San Carlos, California
Research Facility
San Francisco, California
Research Facility
Lakewood, Colorado
Research Facility
Littleton, Colorado
Research Facility
Hamden, Connecticut
Research Facility
DeLand, Florida
Research Facility
Harbor Village, Florida
Research Facility
Hollywood, Florida
Research Facility
Jacksonville, Florida
Research Facility
Panama City, Florida
Research Facility
Zephyrhills, Florida
Research Facility
Atlanta, Georgia
Research Facility
Savannah, Georgia
Research Facility
Arlington Heights, Illinois
Research Facility
Chicago, Illinois
Research Facility
Topeka, Kansas
Research Facility
Louisville, Kentucky
Research Facility
Baton Rouge, Louisiana
Research Facility
Shreveport, Louisiana
Research Facility
Baltimore, Maryland
Research Facility
Chevy Chase, Maryland
Research Facility
Reisterstown, Maryland
Research Facility
Boston, Massachusetts
Research Facility
Columbia, Michigan
Research Facility
Minneapolis, Minnesota
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.